ABIOSA PHARMA AS: årsregnskap 2023 vs 2022
Another loss-making year
approved 2024-06-23; registry 2024-07-20; journal 2024 655095
Summary
What changed
Comparing Årsregnskap 2023 with 2022 for ABIOSA PHARMA AS. Net result -300 NOK → -2 486 NOK. Equity -9 184 NOK → -11.7k NOK.
Pressures included: operating result weakened; net result weakened; equity eroded.
Also worth watching: thin equity buffer. All figures are taken from the published annual accounts for ABIOSA PHARMA AS.
At a glance
Scorecard
What deteriorated
-
↓
Operating result weakened
Operating result -300 NOK → -2 486 NOK. Calculated
-
↓
Net result weakened
Net result -300 NOK → -2 486 NOK. Calculated
-
↓
Equity eroded
Book equity -9 184 NOK → -11.7k NOK (equity ratio -127.9% → -248.7%). Calculated
-
↓
Cash fell
Bank deposits 7 179 NOK → 4 693 NOK (-34.6% YoY). Calculated
Things to notice
-
·
Thin equity buffer
Equity ratio is -248.7% of assets — limited loss-absorbing capacity on a stand-alone basis. Interpretation